Becton Dickinson & CO 8-K filings
NYSE
Becton, Dickinson and Company held its 2025 Annual Meeting on January 28, 2025, and all director nominees were elected, the appointment of Ernst & Young as the independent accounting firm was ratified, and executive compensation was approved.
NYSE
Becton, Dickinson and Company has appointed Pamela Spikner as Senior Vice President, Chief Accounting Officer and Controller, effective January 20, 2025.
NYSE
8-K: Becton Dickinson Reports Strong Q4 and Full Year Fiscal 2024 Results, Issues Positive FY25 Guidance
Becton Dickinson (BD) announced strong fourth quarter and full year fiscal 2024 results, driven by growth and margin execution, and provided an optimistic outlook for fiscal year 2025.
NYSE
Becton Dickinson has reached an agreement to resolve the majority of its existing hernia litigation, with the settlement amount covered by existing reserves and paid out over multiple years.
NYSE
Becton Dickinson has announced a leadership change, with Thomas Spoerel transitioning to Senior Vice President, CFO Regions, and Christopher DelOrefice assuming the role of principal accounting officer on an interim basis.
NYSE
Becton Dickinson (BD) announced strong third-quarter fiscal 2024 results, driven by margin expansion and increased cash flow, leading to an increase in full-year adjusted EPS guidance.
NYSE
Becton, Dickinson and Company has secured a one-year extension on its $2.75 billion revolving credit facility, pushing the maturity date to September 2027.
NYSE
Becton Dickinson has successfully raised $2.4 billion through a multi-currency debt offering to fund its acquisition of Edwards Lifesciences' critical care business.
NYSE
Becton Dickinson (BD) has announced a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash, aiming to expand its smart connected care solutions.
NYSE
Becton Dickinson reported strong second-quarter results, driven by margin execution and increased cash flow, leading to an upward revision of its full-year adjusted EPS guidance.
NYSE
Becton, Dickinson and Company (BD) has announced the retirement of Executive Vice President and President of the Life Sciences segment, David Hickey, effective July 1, 2024.
NYSE
Becton, Dickinson and Company (BD) has issued new Euro and USD denominated notes to refinance existing debt and for general corporate purposes.
NYSE
8-K: Becton, Dickinson and Company Announces $1.175 Billion USD and €750 Million Euro Debt Offerings
Becton, Dickinson and Company (BD) has entered into agreements for a $1.175 billion USD and €750 million Euro debt offering to repay existing debt and for general corporate purposes.
NYSE
Becton Dickinson reported strong first-quarter results, driven by margin execution and increased cash flow, leading to raised full-year guidance for both revenue and earnings per share.
NYSE
Becton, Dickinson and Company held its 2024 Annual Meeting on January 23, 2024, where all director nominees were elected, the appointment of Ernst & Young as the independent auditor was ratified, and executive compensation was approved on an advisory basis.